Page 149 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 149
42. Shao YH, Demissie K, Shih W, et al. 53. Gilliland FD, Hunt WC, Key CR. Ethnic
Contemporary risk profile of prostate cancer variation in prostate cancer survival in New
in the United States. J Natl Cancer Inst Mexico. Cancer Epidemiol Biomarkers Prev
2009;101:1280-1283. 1996;5:247-251.
43. Merrill RM, Potosky AL, Feuer EJ. 54. Gilliland FD, Gleason DF, Hunt WC, et al.
Changing trends in U.S. prostate cancer Trends in Gleason score for prostate cancer
incidence rates. J Natl Cancer Inst diagnosed between 1983 and 1993. J Urol
1996;88:1683-1685. 2001;165:846-850.
44. Stewart SL, King JB, Thompson TD, et al. 55. Newcomer LM, Stanford JL, Blumenstein
Cancer mortality surveillance--United BA, et al. Temporal trends in rates of
States, 1990-2000. MMWR Surveill Summ prostate cancer: declining incidence of
2004;53:1-108. advanced stage disease, 1974 to 1994. J Urol
1997;158:1427-1430.
45. Zhu K, Devesa SS, Wu H, et al. Cancer
incidence in the U.S. military population: 56. Stephenson RA, Smart CR, Mineau GP, et
comparison with rates from the SEER al. The fall in incidence of prostate
program. Cancer Epidemiol Biomarkers carcinoma. On the down side of a prostate
Prev 2009;18:1740-1745. specific antigen induced peak in incidence—
46. Polednak AP. Black-white differences in data from the Utah Cancer Registry. Cancer
1996;77:1342-1348.
tumor grade (aggressiveness) at diagnosis of
prostate cancer, 1992-1998. Ethn Dis 57. Potosky AL, Miller BA, Albertsen PC, et al.
2002;12:536-540. The role of increasing detection in the rising
47. Underwood III W, Jackson J, Wei JT, et al. incidence of prostate cancer. JAMA
1995;273:548-552.
Racial treatment trends in localized/regional
prostate carcinoma: 1992-1999. Cancer 58. Klabunde CN, Potosky AL, Harlan LC, et
2005;103:538-545. al. Trends and black/white differences in
treatment for nonmetastatic prostate cancer.
48. Underwood W, De MS, Ubel P, et al. Med Care 1998;36:1337-1348.
Racial/ethnic disparities in the treatment of
localized/regional prostate cancer. J Urol 59. Sheikh K, Bullock C. Rise and fall of radical
2004;171:1504-1507. prostatectomy rates from 1989 to 1996.
Urology 2002;59:378-382.
49. Demers RY, Swanson GM, Weiss LK, et al.
Increasing incidence of cancer of the 60. Godley PA, Schenck AP, Amamoo MA, et
prostate. The experience of black and white al. Racial differences in mortality among
men in the Detroit metropolitan area. Arch Medicare recipients after treatment for
Intern Med 1994;154:1211-1216. localized prostate cancer. J Natl Cancer Inst
2003;95:1702-1710.
50. Severson RK, Montie JE, Porter AT, et al.
Recent trends in incidence and treatment of 61. Zeliadt SB, Potosky AL, Etzioni R, et al.
prostate cancer among elderly men. J Natl Racial disparity in primary and adjuvant
Cancer Inst 1995;87:532-534. treatment for nonmetastatic prostate cancer:
SEER-Medicare trends 1991 to 1999.
51. Demers RY, Tiwari A, Wei J, et al. Trends Urology 2004;64:1171-1176.
in the utilization of androgen-deprivation
therapy for patients with prostate carcinoma 62. Carpenter WR, Howard DL, Taylor YJ, et
suggest an effect on mortality. Cancer al. Racial differences in PSA screening
2001;92:2309-2317. interval and stage at diagnosis. Cancer
52. Schwartz KL, Grignon DJ, Sakr WA, et al. Causes Control 2010;21:1071-1080.
Prostate cancer histologic trends in the 63. Mullins CD, Onukwugha E, Bikov K, et al.
metropolitan Detroit area, 1982 to 1996. Health disparities in staging of SEER-
Urology 1999;53:769-774. medicare prostate cancer patients in the
United States. Urology 2010;76:566-572.
95
